These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 32270928)

  • 21. Development of In Vitro Drug-Induced Cardiotoxicity Assay by Using Three-Dimensional Cardiac Tissues Derived from Human Induced Pluripotent Stem Cells.
    Takeda M; Miyagawa S; Fukushima S; Saito A; Ito E; Harada A; Matsuura R; Iseoka H; Sougawa N; Mochizuki-Oda N; Matsusaki M; Akashi M; Sawa Y
    Tissue Eng Part C Methods; 2018 Jan; 24(1):56-67. PubMed ID: 28967302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protein-encapsulated doxorubicin reduces cardiotoxicity in hiPSC-cardiomyocytes and cardiac spheroids while maintaining anticancer efficacy.
    Arzt M; Gao B; Mozneb M; Pohlman S; Cejas RB; Liu Q; Huang F; Yu C; Zhang Y; Fan X; Jenkins A; Giuliano AE; Burridge PW; Cui X; Sharma A
    Stem Cell Reports; 2023 Oct; 18(10):1913-1924. PubMed ID: 37657447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Automated image analysis system for studying cardiotoxicity in human pluripotent stem cell-Derived cardiomyocytes.
    Cao L; der Meer ADV; Verbeek FJ; Passier R
    BMC Bioinformatics; 2020 May; 21(1):187. PubMed ID: 32408861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiotoxicity evaluation using human embryonic stem cells and induced pluripotent stem cell-derived cardiomyocytes.
    Zhao Q; Wang X; Wang S; Song Z; Wang J; Ma J
    Stem Cell Res Ther; 2017 Mar; 8(1):54. PubMed ID: 28279214
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Evaluation of Contractile Function Using Human iPS Cell-derived Cardiomyocytes].
    Kurokawa J; Shimizu S; Sakamoto K
    Yakugaku Zasshi; 2024; 144(3):251-255. PubMed ID: 38432933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells.
    Sharma A; Burridge PW; McKeithan WL; Serrano R; Shukla P; Sayed N; Churko JM; Kitani T; Wu H; Holmström A; Matsa E; Zhang Y; Kumar A; Fan AC; Del Álamo JC; Wu SM; Moslehi JJ; Mercola M; Wu JC
    Sci Transl Med; 2017 Feb; 9(377):. PubMed ID: 28202772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anthracycline-Induced Cardiotoxicity: Molecular Insights Obtained from Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs).
    Bozza WP; Takeda K; Alterovitz WL; Chou CK; Shen RF; Zhang B
    AAPS J; 2021 Mar; 23(2):44. PubMed ID: 33719006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes.
    Karhu ST; Kinnunen SM; Tölli M; Välimäki MJ; Szabó Z; Talman V; Ruskoaho H
    Arch Toxicol; 2020 Jun; 94(6):2113-2130. PubMed ID: 32185414
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of Cardiotoxicity With Stem Cell-based Strategies.
    Stella Stoter AM; Hirt MN; Stenzig J; Weinberger F
    Clin Ther; 2020 Oct; 42(10):1892-1910. PubMed ID: 32938533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrating nonlinear analysis and machine learning for human induced pluripotent stem cell-based drug cardiotoxicity testing.
    Kowalczewski A; Sakolish C; Hoang P; Liu X; Jacquir S; Rusyn I; Ma Z
    J Tissue Eng Regen Med; 2022 Aug; 16(8):732-743. PubMed ID: 35621199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cardiotoxicity risk assessment of anti-cancer drugs and future perspectives].
    Yanagida S; Kawagishi H; Kanda Y
    Nihon Yakurigaku Zasshi; 2024; 159(2):83-89. PubMed ID: 38432924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human Induced Pluripotent Stem Cell (hiPSC)-Derived Cells to Assess Drug Cardiotoxicity: Opportunities and Problems.
    Magdy T; Schuldt AJT; Wu JC; Bernstein D; Burridge PW
    Annu Rev Pharmacol Toxicol; 2018 Jan; 58():83-103. PubMed ID: 28992430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Targeted Metabolomics-Based Assay Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Identifies Structural and Functional Cardiotoxicity Potential.
    Palmer JA; Smith AM; Gryshkova V; Donley ELR; Valentin JP; Burrier RE
    Toxicol Sci; 2020 Apr; 174(2):218-240. PubMed ID: 32040181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
    Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
    Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: effects of reference compounds.
    Himmel HM
    J Pharmacol Toxicol Methods; 2013; 68(1):97-111. PubMed ID: 23702537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional and Transcriptional Characterization of Histone Deacetylase Inhibitor-Mediated Cardiac Adverse Effects in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Kopljar I; Gallacher DJ; De Bondt A; Cougnaud L; Vlaminckx E; Van den Wyngaert I; Lu HR
    Stem Cells Transl Med; 2016 May; 5(5):602-12. PubMed ID: 27034410
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integration of mechanical conditioning into a high throughput contractility assay for cardiac safety assessment.
    Goßmann M; Linder P; Thomas U; Juhasz K; Lemme M; George M; Fertig N; Dragicevic E; Stoelzle-Feix S
    J Pharmacol Toxicol Methods; 2020 Sep; 105():106892. PubMed ID: 32629160
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-Cell Transcriptomics of Engineered Cardiac Tissues From Patient-Specific Induced Pluripotent Stem Cell-Derived Cardiomyocytes Reveals Abnormal Developmental Trajectory and Intrinsic Contractile Defects in Hypoplastic Right Heart Syndrome.
    Lam YY; Keung W; Chan CH; Geng L; Wong N; Brenière-Letuffe D; Li RA; Cheung YF
    J Am Heart Assoc; 2020 Oct; 9(20):e016528. PubMed ID: 33059525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multi-lineage heart-chip models drug cardiotoxicity and enhances maturation of human stem cell-derived cardiovascular cells.
    Mozneb M; Jenkins A; Sances S; Pohlman S; Workman MJ; West D; Ondatje B; El-Ghazawi K; Woodbury A; Garcia VJ; Patel S; Arzt M; Dezem F; Laperle AH; Moser VA; Ho R; Yucer N; Plummer J; Barrett RJ; Svendsen CN; Sharma A
    Lab Chip; 2024 Feb; 24(4):869-881. PubMed ID: 38252454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Measuring the contractile forces of human induced pluripotent stem cell-derived cardiomyocytes with arrays of microposts.
    Rodriguez ML; Graham BT; Pabon LM; Han SJ; Murry CE; Sniadecki NJ
    J Biomech Eng; 2014 May; 136(5):051005. PubMed ID: 24615475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.